The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques

W. A. Burgers, Z. Ginbot, Y.-J. Shen, G. K. Chege, A. P. Soares, T. L. Muller, R. Bunjun, A. Kiravu, H. Munyanduki, N. Douglass, A.-L. Williamson
2014 Journal of General Virology  
Poxvirus vectors represent promising human immunodeficiency virus (HIV) vaccine candidates and were a component of the only successful HIV vaccine efficacy trial to date. We tested the immunogenicity of a novel recombinant capripoxvirus vector, lumpy skin disease virus (LSDV), in combination with modified vaccinia Ankara (MVA), both expressing genes from HIV-1. Here, we demonstrated that the combination regimen was immunogenic in rhesus macaques, inducing high-magnitude, broad and balanced CD4
more » ... and CD8 + T-cell responses, and transient activation of the immune response. These studies support further development of LSDV as a vaccine vector. 3These authors contributed equally to this work.
doi:10.1099/vir.0.067835-0 pmid:24866849 fatcat:ai7whrv7cvbcxohi2o6tkwcxfu